Organofluorides

Addex Therapeutics to Release Full-Year 2020 Financial Results and Host Conference Call on March 11, 2021

Retrieved on: 
Tuesday, March 9, 2021
Dipraglurant, Imidazopyridines, Organofluorides, Organ systems, Dystonia, Blepharospasm, Neuroscience, Chemistry

Geneva, Switzerland, March 9, 2021 Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it will issue its full-year 2020 financial results on Thursday March 11, 2021.

Key Points: 
  • Geneva, Switzerland, March 9, 2021 Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it will issue its full-year 2020 financial results on Thursday March 11, 2021.
  • 1: In the 10 minutes prior to the call start time, call the appropriateparticipant dial-in number.
  • Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in H1 2021.
  • Addex is listed on the SIX Swiss Exchange and the NASDAQ Capital Market and trades under the ticker symbol "ADXN".

FASN Inhibitor ASC40 Demonstrates Positive Phase 2 Topline Clinical Results from China Cohort of Patients with NASH

Retrieved on: 
Tuesday, March 9, 2021
Chemical compounds, Pyrimidines, Organic compounds, Organofluorides, Chemistry, Pyrrolidines, Orphan drugs, Ureas, Brilacidin

These data from the China cohort are consistent with those of the US cohort, previously reported at the AASLD Liver Meeting in November 2020.

Key Points: 
  • These data from the China cohort are consistent with those of the US cohort, previously reported at the AASLD Liver Meeting in November 2020.
  • "Based on the positive Phase 2 data, we have selected doses for the Phase 2b/3 NASH trial in China."
  • The China cohort of this Phase 2 trial evaluated the safety and efficacy of an oral, once-daily dosing of 50 mg of ASC40 or matching placebo for 12 weeks in 30 patients with NASH.
  • In 63% of patients on ASC40 ALT decreased by17 U/L or greater, which has been shown to correlate with liver biopsy response in NASH patients.

Global High Performance Fluoropolymers Market Forecasts to 2025 - 7% CAGR Forecast Between 2020 and 2025 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 5, 2021
Chemicals, Plastics, Manufacturing, Organic polymers, Chemistry, Physical sciences, Thermoplastics, Fluoropolymers, Plastics, Organofluorides, Copolymers, Polytetrafluoroethylene, ETFE, HPFS, Fluorine

The "High Performance Fluoropolymers Market by Type (PTFE, FEP, PFA/MFA, ETFE), Form (Granular, Fine Powder & Dispersion), End-use Industry (Industrial Processing, Transportation, Electrical & Electronics, Medical), and Region - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "High Performance Fluoropolymers Market by Type (PTFE, FEP, PFA/MFA, ETFE), Form (Granular, Fine Powder & Dispersion), End-use Industry (Industrial Processing, Transportation, Electrical & Electronics, Medical), and Region - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
  • The global market size of HPFs was USD 3,300.9 million in 2019 and is projected to reach USD 4,272.7 million by 2025, at a CAGR of 7.0% between 2020 and 2025.
  • PTFE is the most widely used type of HPF and accounted for the largest market share.
  • HPFs market is segmented on the basis of end-use industry as industrial processing, transportation, medical, electrical & electronics, and others.

Global Polychlorotrifluoroethylene Market (2021 to 2029) - Featuring Daikin, Honeywell and Arkema Among Others

Retrieved on: 
Thursday, March 4, 2021
Thermoplastics, Organofluorides, Fluoropolymers, Polychlorotrifluoroethylene, Marketplace, Compound annual growth rate, Chlorotrifluoroethylene, Market segmentation, Chemistry, Applied mathematics, Academic disciplines

The polychlorotrifluoroethylene market is set to reach US$ 795 million from around US$ 540 million in 2019.

Key Points: 
  • The polychlorotrifluoroethylene market is set to reach US$ 795 million from around US$ 540 million in 2019.
  • The market is expected to grow at the rate of 4% CAGR during the forecast period of 2021 to 2029.
  • What is the key impact of Covid 19 over market revenues and market determinants in the PCTFE market?
  • How to overcome the current market challenges and leverage the opportunities in each of the market segment?

Ocular Therapeutix™ Announces FDA Acceptance of Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

Retrieved on: 
Thursday, March 4, 2021
Research, FDA, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Optical, Science, Other Science, Medical specialties, Clinical medicine, Medicine, Organofluorides, Pregnanes, Conjunctivitis, Measles, Allergic conjunctivitis, Dexamethasone, ISTA Pharmaceuticals, Brimonidine/timolol, DEXTENZA, Ocular Therapeutix, Inc.

If approved, this sNDA would include the treatment of ocular itching associated with allergic conjunctivitis as an additional approved indication of DEXTENZA.

Key Points: 
  • If approved, this sNDA would include the treatment of ocular itching associated with allergic conjunctivitis as an additional approved indication of DEXTENZA.
  • DEXTENZA is FDA approved for the treatment of ocular inflammation and pain following ophthalmic surgery.
  • Ocular Therapeutixs first commercial drug product, DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery.
  • Ocular Therapeutix has also submitted a Supplemental NDA for DEXTENZA to include the treatment of ocular itching associated with allergic conjunctivitis as an additional approved indication.

Optinose Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights

Retrieved on: 
Wednesday, March 3, 2021
Clinical medicine, Fluticasone propionate, Glucocorticoids, Organofluorides, Respiratory therapy, Thioesters, Pulmonology, Health care

Following pandemic-related disruption in second quarter, we achieved consecutive all-time highs for new prescriptions of XHANCE in third and fourth quarter 2020.

Key Points: 
  • Following pandemic-related disruption in second quarter, we achieved consecutive all-time highs for new prescriptions of XHANCE in third and fourth quarter 2020.
  • The number of XHANCE (fluticasone propionate) prescriptions increased by 36% from 54,300 in the fourth quarter 2019 to 73,900 in the fourth quarter 2020.
  • The number of new prescriptions for XHANCE increased by 16% from 21,200 in the fourth quarter of 2019 to 24,600 in the fourth quarter of 2020.
  • This includes the Company's expectation that first quarter 2021 XHANCE net revenue will decrease compared to fourth quarter 2020.

Insights on the Polychlorotrifluoroethylene Global Market to 2029 - by Application, End-use and Region - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 2, 2021
Chemicals, Plastics, Manufacturing, Thermoplastics, Organofluorides, Fluoropolymers, Polychlorotrifluoroethylene, Chlorotrifluoroethylene, Chemistry, Chemical compounds, Physical sciences

The "Polychlorotrifluoroethylene Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 To 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Polychlorotrifluoroethylene Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 To 2029" report has been added to ResearchAndMarkets.com's offering.
  • The polychlorotrifluoroethylene market is set to reach US$ 795 million from around US$ 540 million in 2019.
  • The market is expected to grow at the rate of 4% CAGR during the forecast period of 2021 to 2029.
  • China continues to be the largest market in the world for PCTFE owing to its large network of manufacturing centers and pharmaceutical companies.

Global High-performance Plastics Markets in Industrial Applications, 2020-2027 - Future Growth Potential Enhanced by Growth Opportunities in Equipment Protection Applications

Retrieved on: 
Thursday, February 18, 2021
Chemistry, Physical sciences, Organofluorides, Natural sciences, Thermoplastics, Plastics, Polymers, Fluoropolymers, Tetrafluoroethylene, Polyvinylidene fluoride, Fluorine, Ketone

This research service analyses the global market for HPP in industrial applications.

Key Points: 
  • This research service analyses the global market for HPP in industrial applications.
  • Fluoropolymers considered in this study include poly tetraflouroethylene (PTFE), polyvinylidene fluoride (PVDF), ethylene tetrafluoroethylene (ETFE), and fluorinated ethylene propylene (FEP).
  • Fluoropolymers are further segmented by two end-use applications - chemical industries (including food and pharmaceuticals) and renewable energy/energy storage.
  • HPP Market in Industrial Applications, Scope of Analysis
    Revenue and Volume Shipment Forecast, HPP in Industrial Applications
    Revenue Forecast by HPP Chemistry, HPP in Industrial Applications
    Revenue Forecast Analysis by Region, HPP in Industrial Applications
    Pricing Trends and Forecast Assumptions, Fluoropolymers
    Revenue and Volume Shipment Forecast, Fluoropolymers
    Volume Shipment Forecast by Chemistry, Fluoropolymers
    Volume Shipment Forecast by Industry, Fluoropolymers
    Revenue and Volume Forecast Analysis, Fluoropolymers
    Volume Shipment Forecast by Region, Fluoropolymers
    Revenue and Volume Shipment Forecast Analysis by Region, Fluoropolymers
    Pricing Trends and Forecast Assumptions, Ether Ketones
    Revenue and Volume Shipment Forecast, Ether Ketones
    Volume Shipment Forecast by Chemistry, Ether Ketones
    Volume Shipment Forecast by Industry, Ether Ketones
    Revenue and Volume Shipment Forecast, Ether Ketones
    Volume Shipment Forecast by Region, Ether Ketones
    Revenue and Volume Shipment Forecast Analysis by Region, Ether Ketones
    Pricing Trends and Forecast Assumptions, Polyarylsulfones
    Revenue and Volume Shipment Forecast, Polyarylsulfones
    Volume Shipment Forecast by Chemistry, Polyarylsulfones
    Revenue and Volume Shipment Forecast Analysis, Polyarylsulfones
    Volume Shipment Forecast by Region, Polyarylsulfones
    Revenue and Volume Shipment Forecast Analysis by Region, Polyarylsulfones
    Pricing Trends and Forecast Assumptions, Polyphenylene Sulfide
    Revenue and Volume Shipment Forecast, Polyphenylene Sulfide
    Revenue and Volume Shipment Forecast Analysis, Polyphenylene Sulfide
    Volume Shipment Forecast by Region, Polyphenylene Sulfide
    Revenue and Volume Shipment Forecast Analysis by Region, Polyphenylene Sulfide
    Growth Opportunity 1 - Investment in Protection of Manufacturing Equipment for Increased Production Efficiency, 2020
    Growth Opportunity 2 - Investment in New Product Development to Accelerate the Transition to Industry 4.0/5.0, 2020

vTv Therapeutics Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

Retrieved on: 
Wednesday, February 17, 2021
Phosphodiesterase-4 inhibitor, Psoriasis, Phosphodiesterase 4, Organ systems, Organofluorides, Medical specialties, Pyrimidines

This randomized, double-blind, placebo-controlled, multiple ascending dose study will evaluate up to 3 doses of HPP737 administered for 14 days in healthy volunteers.

Key Points: 
  • This randomized, double-blind, placebo-controlled, multiple ascending dose study will evaluate up to 3 doses of HPP737 administered for 14 days in healthy volunteers.
  • The goal of this study is to determine the maximum tolerated dose with minimal or no gastrointestinal intolerance to inform dose selection for a phase 2 study in psoriasis which is planned for later this year.
  • HPP737 is a novel, potent, orally administered PDE4 inhibitor discovered by vTv Therapeutics.
  • PDE4 has been demonstrated to be a validated therapeutic target for the treatment of a variety of disorders including psoriasis.

Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million

Retrieved on: 
Wednesday, February 17, 2021
Enzyme kinetics, Organic compounds, Imidazopyridines, Chemistry, Dipraglurant, Organofluorides, Chemical compounds, Allosteric regulation, Allosteric modulator, ASD

Geneva, Switzerland, February 17, 2021 Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it completed 2020 with a strong cash position of CHF18.7 million of cash and cash equivalents.

Key Points: 
  • Geneva, Switzerland, February 17, 2021 Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it completed 2020 with a strong cash position of CHF18.7 million of cash and cash equivalents.
  • We have maintained readiness to start our pivotal study of dipraglurant for PD-LID and expect to dose patients in the first half 2021, said Tim Dyer, CEO of Addex.
  • Cash and cash equivalents at December 31, 2020 of CHF18.7 million
    Net cash used in 2020 of CHF12.8 million, in line with expectations
    Indivior gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) partnership research term extended to June 2021.
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.